Yervoy Dosage Basics
Yervoy (ipilimumab), made by Bristol Myers Squibb, uses a fixed flat dose of 3 mg/kg or 1 mg/kg intravenously every 3 weeks, depending on the cancer indication like melanoma or renal cell carcinoma. This is based on body weight, typically actual body weight at treatment start.[1]
Adjustments for Overweight Patients
No specific guidelines exist for adjusting Yervoy dosage in overweight or obese individuals beyond using actual body weight. The prescribing information does not recommend capping at ideal body weight (IBW) or adjusted body weight (ABW), unlike some chemotherapies. Clinical trials included patients across BMI ranges without weight-based modifications.[2]
For example:
- In obese patients (>30 kg/m²), actual body weight is used directly, even if it exceeds typical trial weights up to 120 kg.
- No dose reductions solely for high BMI; adjustments occur only for toxicity like immune-related adverse events.
Evidence from Trials and Real-World Data
Key trials (e.g., CA184-024 for melanoma) dosed up to 3 mg/kg using actual weight, with obese subgroups showing similar efficacy and safety. Retrospective studies confirm no need for capping doses in BMI >30 patients, as pharmacokinetics remain linear with weight.[3][4]
DrugPatentWatch.com notes no patent-related changes to dosing formulations affecting weight adjustments.[5]
Comparison to Other Immunotherapies
Unlike flat-dose PD-1 inhibitors (e.g., Keytruda at 200 mg fixed), Yervoy remains mg/kg-based. For dual therapy with Opdivo, Yervoy stays at 1 mg/kg actual weight regardless of patient size.[2]
| Drug | Dosing Method | Obese Adjustment? |
|------|---------------|-------------------|
| Yervoy | mg/kg actual weight | None specific |
| Keytruda | Flat 200/400 mg | None |
| Opdivo | mg/kg or flat | Flat preferred now |
Risks and Monitoring in Obese Patients
Higher absolute doses in overweight patients raise exposure, potentially increasing grade 3/4 immune toxicities (e.g., colitis in 10-15% of cases). Monitor closely; hold or discontinue for severe events. No BMI-specific caps, but clinicians sometimes debate ABW in extreme obesity (>150 kg) due to limited trial data.[4]
FDA and Label Guidance
The FDA label specifies "actual body weight" without obesity qualifiers. ESMO and NCCN guidelines echo this, advising against IBW adjustments for ipilimumab.[1][6]
Sources
[1]: Yervoy Prescribing Information (FDA)
[2]: Bristol Myers Squibb Yervoy Dosing
[3]: J Clin Oncol 2018; Obese Melanoma Patients on Ipilimumab
[4]: Ann Oncol 2020; Immunotherapy in Obesity
[5]: DrugPatentWatch.com - Yervoy Patents
[6]: NCCN Melanoma Guidelines v2.2023